Disease Modifying Therapies in MS: Highlights from ACTRIMS 2018

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Disease Modifying Therapies in MS: Highlights from ACTRIMS 2018

Disease Modifying Therapies in MS: Highlights from ACTRIMS 2018
Dr. Leist and Dr. Markowitz discuss key takeaways from the recent 2018 ACTRIMS meeting in San Diego, CA.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Multiple sclerosis is a quickly advancing field of medicine. The data presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) meeting heavily focused on new and emerging concepts, including immune cell populations in the pathophysiology of MS. Join Dr. Thomas Leist and Dr. Clyde Markowitz as they review these advances.

    Disclaimer: Some products discussed in this activity have not received regulatory approval by the US FDA for the treatment of patients with Multiple Sclerosis. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement."

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 


    Thomas T. Leist, MD
    Chief, Division Clinical Neuroimmunology
    Director, Comprehensive Multiple Sclerosis Center
    Thomas Jefferson University
    Philadelphia, PA

    Dr. Thomas Leist has disclosed he receives consulting and speaker fees from Biogen, EMD Serono, Sanofi-Genzyme, Genentech, Novartis, and Teva Neuroscience.

    Clyde E. Markowitz, MD
    Director, Multiple Sclerosis Center
    Associate Professor of Neurology
    University of Pennsylvania
    Philadelphia, PA

    Dr. Clyde Markowitz has disclosed he receives consulting fees from Bayer, Biogen, EMD Serono, Genetec, Novartis, Roche, Sanofi-Genzyme, and Teva Neuroscience.


    • Sean Barrett has nothing to disclose.
    • Carole Drexel, PhD has nothing to disclose.
    • Ann Early has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Summarize the increasing volume of evidence for a role of both immune and non-immune cell populations in the pathophysiology of MS and its potential impact on agent selections to manage MS
    • Discuss current evidence related to long term efficacy and safety of intermittently dosed medications for MS, including concerns related to lymphopenia, infection, and malignancy
  • Target Audience

    This activity is designed to meet the educational needs of practicing neurologists, and other healthcare professionals that manage patients with multiple sclerosis.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at

  • Provider

    TOPEC Global designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and TOPEC Global. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of TOPEC Global you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.